Bioinvent

BioInvent International is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer.[1] The company was founded in 1983 by Carl Borrebaeck and is listed on the Stockholm Stock Exchange since 2001. The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. Martin Welschof has been CEO since 2018.[2][3][4][5][6][7]

References
  1. Maria Phillips, "Bioinvent rasar efter emissionsbesked", Dagens industri, 25 February 2019 (in Swedish).
  2. "BioInvent rekryterar Martin Welschof som ny vd" (press release), Cision, 12 April 2018 (in Swedish).
  3. "BioInvent International", Avanza Bank, retrieved 19 June 2019 (in Swedish).
  4. "Technology", Bioinvent, retrieved 19 June 2019.
  5. Kajsa-Stina Kalin, "Bioinvent var pionjärer i parken" Sydsvenskan, 4 October 2015 (in Swedish).
  6. Maria Lindh, "Forskningen som ledde till miljardavtalet", LUM., Lund University, 11 September 2015 (in Swedish).
  7. "Bioinvent i nytt cancer–samarbete", Dagens Nyheter, 4 January 2012 (in Swedish; subscription required).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.